Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainChek Ltd ( (AU:PCK) ) has provided an update.
PainChek Ltd has announced the cessation of a tranche of listed options, with 16,653,867 PCKAZ options expiring unexercised on 3 March 2026. The lapse of these options slightly simplifies the company’s capital structure but does not raise new capital, implying no immediate dilution or cash inflow impact for existing shareholders.
The notification formalises the removal of these options from the company’s issued securities on the ASX and reflects standard lifecycle management of expiring convertible instruments. While operational activities are unaffected, the change may modestly alter future potential equity overhang and is relevant for investors tracking PainChek’s fully diluted capital base.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
More about PainChek Ltd
PainChek Ltd is a healthcare technology company listed on the ASX, focused on developing and commercialising digital tools for pain assessment. Its securities trade under the ticker PCK, and the company operates within the medical technology sector, providing software-driven solutions to improve clinical pain evaluation and monitoring.
Average Trading Volume: 167,614
Technical Sentiment Signal: Sell
Current Market Cap: A$34.49M
See more insights into PCK stock on TipRanks’ Stock Analysis page.